Financing, Equity Capital Markets
Immunovant, Inc.
09/23
|
$322.0 Million
Âé¶¹´«Ã½ served as bookrunner for Immunovant, Inc. on a follow-on offering and PIPE offering
Sub-Type
Follow-On Offering
Sector
Sub-Sector
Biopharma